The conference features the ever-popular FDA Center Office Updates provided by the Office Directors of CDER, CBER, CVM and the Associate Commissioner of Regulatory Affairs of ORA.
BETHESDA, Md. (PRWEB)
July 27, 2022
The Parenteral Drug Association (PDA) and the US Food and Drug Administration (FDA) are again co-sponsors of the PDA/FDA Joint Regulatory Conference, now in its 31st year. The previous two PDA/FDA Joint Regulatory Conferences were offered as virtual events due to travel and other restrictions due to the COVID-19 pandemic.
This year’s Joint Regulatory Conference will emphasize the role of implementing effective quality systems to ensure continuous control status throughout the life cycle of pharmaceutical products through vigilant management of quality risks. The role of robust systems, facilities, processes, raw material quality, supplier relationships, industrial modernization and quality risk management is emphasized.
Case studies will be presented throughout the conference to provide practical insights into these concepts and to illustrate how sustained compliance with Current Good Manufacturing Practice (CGMP) lays the foundation for drug quality and a reliable supply chain. The conference will also address international collaborations aimed at improving drug quality and benefiting consumers.
The conference features the ever-popular FDA Center Office Updates provided by the Office Directors of CDER, CBER, CVM and the Associate Commissioner of Regulatory Affairs of ORA. The Directors of the FDA Center and ORA’s Associate Commissioner of Regulatory Affairs will discuss current programs, initiatives and trends related to regulatory inspections and enforcement. The conference will also delve deeper into compliance issues. Many sessions of practical GMP solutions and case studies throughout the conference culminating in the actual GMP compliance trends and issues session held towards the end of the conference (a multi-year standing room only session). Just before the closing plenary session, attendees will have lunch with regulators, another popular way for attendees to hear from FDA experts.
For more information, see: https://www.pda.org/global-event-calendar/event-detail/2022-pda-joint-regulatory-conference
Press representatives can request a press pass here: https://www.pda.org/about-pda/press-pass-request-form
Via PDA – Connecting People, Science and Regulation®
The Parenteral Drug Association (PDA) is the world’s leading provider of scientific, technological and regulatory information and education to the pharmaceutical and biopharmaceutical community. Founded in 1946 as a not-for-profit organization, PDA is committed to developing science-based, practical technical information and resources to advance science and regulation through the expertise of over 10,500 members worldwide. PDA is an ANSI-accredited standards development organization. Go to http://www.pda.org/footer/about-pda to learn more.
Share the article on social media or via email: